These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 32746775

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R.
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [Abstract] [Full Text] [Related]

  • 30. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG, Smith SM, Gums JG.
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [Abstract] [Full Text] [Related]

  • 31. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
    Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R.
    Neurology; 2019 May 07; 92(19):e2250-e2260. PubMed ID: 30996060
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW, Blumenfeld AM, Halker Singh RB, Williams R, Zhang F, Chen PW, Hsu CP, Peng C, Snellman J, Chehrenama M, Ailani J.
    Headache; 2023 Feb 07; 63(2):233-242. PubMed ID: 36226464
    [Abstract] [Full Text] [Related]

  • 34. Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis.
    Yang Y, Chen M, Wu D, Sun Y, Jiang F, Chen Z, Wang Z.
    Curr Neuropharmacol; 2022 Feb 07; 20(2):460-470. PubMed ID: 34429056
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Timing and durability of response to erenumab in patients with chronic migraine.
    Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J, Klatt J, Chou DE, Wang A, Paiva da Silva Lima G.
    Headache; 2021 Sep 07; 61(8):1255-1263. PubMed ID: 34363708
    [Abstract] [Full Text] [Related]

  • 37. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
    Pozo-Rosich P, Dolezil D, Paemeleire K, Stepien A, Stude P, Snellman J, Arkuszewski M, Stites T, Ritter S, Lopez Lopez C, Maca J, Ferraris M, Gil-Gouveia R.
    JAMA Neurol; 2024 May 01; 81(5):461-470. PubMed ID: 38526461
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.
    Hirata K, Takeshima T, Sakai F, Numachi Y, Yoshida R, Koukakis R, Hasebe M, Yui D, da Silva Lima GP, Cheng S.
    BMJ Open; 2023 Aug 18; 13(8):e068616. PubMed ID: 37597868
    [Abstract] [Full Text] [Related]

  • 40. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G, Hill B, Murphy M, Tylova I, Andreou AP.
    J Headache Pain; 2020 Jun 01; 21(1):61. PubMed ID: 32487102
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.